Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIA, Multicenter, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 Given as Monotherapy and in Combination With Pembrolizumab, in Unresectable Metastatic Solid Tumours

Trial Profile

A Phase I/IIA, Multicenter, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 Given as Monotherapy and in Combination With Pembrolizumab, in Unresectable Metastatic Solid Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs AGI 134 (Primary) ; Pembrolizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Agalimmune
  • Most Recent Events

    • 08 Nov 2018 According to a BioLineRx media release, initial safety results from part 1 of the trial are anticipated in second half of 2019.
    • 13 Aug 2018 Status changed from not yet recruiting to recruiting, according to a BioLineRx media release.
    • 01 Aug 2018 According to a BioLineRx media release, this study will take place in the UK and Israel, with possible expansion to the US and additional countries in Europe in 2019 and first results from this study are expected by the end of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top